Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dai Chihara

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Blood Advances|September 25, 2024
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literatureCôme Bommier, Brian K Link, Brianna J Gysbers, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Blood Cancer Journal|July 2, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphomaKaran L Chohan, Eduardo Edelman Saul, R Eric Davis, et al.
Haematologica|November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphomaMatthew J Maurer, Carla Casulo, Melissa C Larson, et al.
Blood Advances|November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO ConsortiumJonathan R Day, Melissa C Larson, Urshila Durani, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
JAMA Network Open|April 7, 2025
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T TherapyJames P Long, Rishab Prakash, Paul Edelkamp, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2024
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell TherapyGohar S Manzar, Susan Y Wu, Stephanie O Dudzinski, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Blood Advances|September 25, 2024
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literatureCôme Bommier, Brian K Link, Brianna J Gysbers, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Blood Cancer Journal|July 2, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphomaKaran L Chohan, Eduardo Edelman Saul, R Eric Davis, et al.
Haematologica|November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphomaMatthew J Maurer, Carla Casulo, Melissa C Larson, et al.
Blood Advances|November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO ConsortiumJonathan R Day, Melissa C Larson, Urshila Durani, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
JAMA Network Open|April 7, 2025
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T TherapyJames P Long, Rishab Prakash, Paul Edelkamp, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2024
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell TherapyGohar S Manzar, Susan Y Wu, Stephanie O Dudzinski, et al.
Pageof 13